Patents by Inventor Robert Hershberg

Robert Hershberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for the therapy and diagnosis of Inflammatory Bowel Disease
    Patent number: 10981978
    Abstract: Compositions and methods for the therapy and diagnosis of Inflammatory Bowel Disease (IBD), including Crohn's Disease and Ulcerative Colitis, are disclosed. Illustrative compositions comprise one or more bacterial polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of IBD.
    Type: Grant
    Filed: September 13, 2019
    Date of Patent: April 20, 2021
    Assignee: CORIXA CORPORATION
    Inventors: Robert Hershberg, Nancy Ann Hosken, Michael J. Lodes, Raodoh Mohamath
  • COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF INFLAMMATORY BOWEL DISEASE
    Publication number: 20200181244
    Abstract: Compositions and methods for the therapy and diagnosis of Inflammatory Bowel Disease (IBD), including Crohn's Disease and Ulcerative Colitis, are disclosed. Illustrative compositions comprise one or more bacterial polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of IBD.
    Type: Application
    Filed: September 13, 2019
    Publication date: June 11, 2020
    Inventors: Robert Hershberg, Nancy Ann Hosken, Michael J. Lodes, Raodoh Mohamath
  • Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
    Patent number: 10457722
    Abstract: Compositions and methods for the therapy and diagnosis of Inflammatory Bowel Disease (IBD), including Crohn's Disease and Ulcerative Colitis, are disclosed. Illustrative compositions comprise one or more bacterial polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of IBD.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: October 29, 2019
    Assignee: Corixa Corporation
    Inventors: Robert Hershberg, Nancy Ann Hosken, Michael J. Lodes, Raodoh Mohamath
  • COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF INFLAMMATORY BOWEL DISEASE
    Publication number: 20180362622
    Abstract: Compositions and methods for the therapy and diagnosis of Inflammatory Bowel Disease (IBD), including Crohn's Disease and Ulcerative Colitis, are disclosed. Illustrative compositions comprise one or more bacterial polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of IBD.
    Type: Application
    Filed: June 22, 2018
    Publication date: December 20, 2018
    Applicant: Corixa Corporation
    Inventors: Robert Hershberg, Nancy Ann Hosken, Michael J. Lodes, Raodoh Mohamath
  • Methods of enhancing antibody-dependent cellular cytotoxicity
    Patent number: 10016440
    Abstract: The application relates to method of increasing antibody-dependent cellular cytotoxicity in a subject receiving therapeutic monoclonal antibody treatment. In some embodiments, methods are provided for administering to subject to a subject in need thereof a therapeutic antibody in conjunction with an ADCC enhancer molecule.
    Type: Grant
    Filed: April 21, 2011
    Date of Patent: July 10, 2018
    Assignee: VentiRx Pharmaceuticals, Inc.
    Inventor: Robert Hershberg
  • Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
    Patent number: 10011650
    Abstract: Compositions and methods for the therapy and diagnosis of Inflammatory Bowel Disease (IBD), including Crohn's Disease and Ulcerative Colitis, are disclosed. Illustrative compositions comprise one or more bacterial polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of IBD.
    Type: Grant
    Filed: January 11, 2018
    Date of Patent: July 3, 2018
    Assignee: Corixa Corporation
    Inventors: Robert Hershberg, Nancy Ann Hosken, Michael J. Lodes, Raodoh Mohamath
  • COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF INFLAMMATORY BOWEL DISEASE
    Publication number: 20180142001
    Abstract: Compositions and methods for the therapy and diagnosis of Inflammatory Bowel Disease (IBD), including Crohn's Disease and Ulcerative Colitis, are disclosed. Illustrative compositions comprise one or more bacterial polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of IBD.
    Type: Application
    Filed: January 11, 2018
    Publication date: May 24, 2018
    Applicant: CORIXA CORPORATION
    Inventors: ROBERT HERSHBERG, NANCY ANN HOSKEN, MICHAEL J. LODES, RAODOH MOHAMATH
  • Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
    Patent number: 9868779
    Abstract: Compositions and methods for the therapy and diagnosis of Inflammatory Bowel Disease (IBD), including Crohn's Disease and Ulcerative Colitis, are disclosed. Illustrative compositions comprise one or more bacterial polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of IBD.
    Type: Grant
    Filed: February 18, 2016
    Date of Patent: January 16, 2018
    Assignee: Corixa Corporation
    Inventors: Robert Hershberg, Nancy Ann Hosken, Michael J. Lodes, Raodoh Mohamath
  • Substituted benzoazepines as toll-like receptor modulators
    Patent number: 9718796
    Abstract: Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, fibrotic disease, cardiovascular disease, infectious disease, inflammatory disorder, graft rejection, or graft-versus-host disease.
    Type: Grant
    Filed: January 12, 2012
    Date of Patent: August 1, 2017
    Assignees: VENTIRX PHARMACEUTICALS, INC., ARRAY BIOPHARMA, INC.
    Inventors: James Jeffry Howbert, Robert Hershberg, Laurence E. Burgess, Hong Woon Yang
  • Substituted benzoazepines as toll-like receptor modulators
    Patent number: 9655904
    Abstract: Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-versus-host disease.
    Type: Grant
    Filed: August 4, 2015
    Date of Patent: May 23, 2017
    Assignees: VENTIRX PHARMACEUTICALS, INC., ARRAY BIOPHARMA, INC.
    Inventors: James Jeffry Howbert, Gregory Dietsch, Robert Hershberg, Laurence E. Burgess, Joseph P. Lyssikatos, Brad Newhouse, Hong-Woon Yang
  • METHODS OF ENHANCING ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY
    Publication number: 20170027954
    Abstract: The application relates to method of increasing antibody-dependent cellular cytotoxicity in a subject receiving therapeutic monoclonal antibody treatment. In some embodiments, methods are provided for administering to subject to a subject in need thereof a therapeutic antibody in conjunction with an ADCC enhancer molecule.
    Type: Application
    Filed: October 11, 2016
    Publication date: February 2, 2017
    Inventor: Robert Hershberg
  • COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF INFLAMMATORY BOWEL DISEASE
    Publication number: 20160362481
    Abstract: Compositions and methods for the therapy and diagnosis of Inflammatory Bowel Disease (IBD), including Crohn's Disease and Ulcerative Colitis, are disclosed. Illustrative compositions comprise one or more bacterial polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of IBD.
    Type: Application
    Filed: February 18, 2016
    Publication date: December 15, 2016
    Applicant: CORIXA CORPORATION
    Inventors: Robert Hershberg, Nancy Ann Hosken, Michael J. Lodes, Raodoh Mohamath, Stephan R. Targan
  • TOLL-LIKE RECEPTOR AGONIST FORMULATIONS AND THEIR USE
    Publication number: 20160331758
    Abstract: The present invention is directed generally to stable formulations of a TLR agonist preferably a TLR7 or a TLR8 agonist, for use in the treatment of cancer, preferably solid tumors and lymphomas. Specifically, the present invention is directed to stable formulations of up to 50 mg/ml of a TLR agonist which comprise a cyclodextrin.
    Type: Application
    Filed: December 21, 2015
    Publication date: November 17, 2016
    Inventors: J. Jeffry Howbert, Muralikrishna Duvvuri, Robert Hershberg, Gregory Dietsch
  • SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS
    Publication number: 20160137608
    Abstract: Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease.
    Type: Application
    Filed: October 13, 2015
    Publication date: May 19, 2016
    Applicants: VENTIRX PHARMACEUTICALS, INC., ARRAY BIOPHARMA, INC.
    Inventors: James Jeffry Howbert, Gregory N. Dietsch, Robert Hershberg, Laurence E. Burgess, George A. Doherty, C. Todd Eary, Robert D. Groneberg, Zachery Jones
  • Substituted Benzoazepines as Toll-Like Receptor Modulators
    Publication number: 20160129010
    Abstract: Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-versus-host disease.
    Type: Application
    Filed: August 4, 2015
    Publication date: May 12, 2016
    Inventors: James Jeffry Howbert, Gregory Dietsch, Robert Hershberg, Laurence E. Burgess, Joseph P. Lyssikatos, Brad Newhouse, Hong-Woon Yang
  • Toll-like receptor agonist formulations and their use
    Patent number: 9216192
    Abstract: The present invention is directed generally to stable formulations of a TLR agonist preferably a TLR7 or a TLR8 agonist, for use in the treatment of cancer, preferably solid tumors and lymphomas. Specifically, the present invention is directed to stable formulations of up to 50 mg/ml of a TLR agonist which comprise a cyclodextrin.
    Type: Grant
    Filed: July 16, 2012
    Date of Patent: December 22, 2015
    Assignee: VentiRx Pharmaceuticals, Inc.
    Inventors: J. Jeffry Howbert, Muralikrishna Duvvuri, Robert Hershberg, Gregory Dietsch
  • Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
    Patent number: 9175046
    Abstract: Compositions and methods for the therapy and diagnosis of Inflammatory Bowel Disease (IBD), including Crohn's Disease and Ulcerative Colitis, are disclosed. Illustrative compositions comprise one or more bacterial polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of IBD.
    Type: Grant
    Filed: November 21, 2012
    Date of Patent: November 3, 2015
    Assignee: Corixa Corporation
    Inventors: Robert Hershberg, Nancy Ann Hosken, Michael J. Lodes, Raodoh Mohamath
  • Substituted benzoazepines as toll-like receptor modulators
    Patent number: 9126940
    Abstract: Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease.
    Type: Grant
    Filed: February 14, 2014
    Date of Patent: September 8, 2015
    Assignees: VentiRx Pharmaceuticals, Inc., Array Biopharma, Inc.
    Inventors: James Jeffry Howbert, Gregory Dietsch, Robert Hershberg, Laurence E. Burgess, Joseph P. Lyssikatos, Brad Newhouse, Hong-Woon Yang
  • Substituted Benzoazepines as Toll-Like Receptor Modulators
    Publication number: 20140234376
    Abstract: Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease.
    Type: Application
    Filed: February 14, 2014
    Publication date: August 21, 2014
    Applicants: Array BioPharma, Inc., VentiRx Pharmaceuticals, Inc.
    Inventors: James Jeffry Howbert, Gregory Dietsch, Robert Hershberg, Laurence E. Burgess, Joseph P. Lyssikatos, Brad Newhouse, Hong-Woon Yang
  • Substituted benzoazepines as toll-like receptor modulators
    Patent number: 8691809
    Abstract: Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease.
    Type: Grant
    Filed: August 18, 2010
    Date of Patent: April 8, 2014
    Assignees: VentiRx Pharmaceuticals, Inc., Array BioPharma, Inc.
    Inventors: James Jeffry Howbert, Gregory Dietsch, Robert Hershberg, Laurence E. Burgess, Joseph P. Lyssikatos, Brad Newhouse, Hong Woon Yang